Tumor-derived antigens in the tumor microenvironment can activate the cGAS-STING pathway, prompting the production of type I IFN, which bolsters dendritic cell maturation and mediates T cell activation, thus igniting anti-tumor immunity. Here, STING1 is linked to neoplasm.